Episode Details

ByteDance is planning a $23 billion investment in AI infrastructure – but it’ll take more than that to match Big Tech – US regulators approved Novo Nordisk’s once-a-day Wegovy pill, handing the Danish drugmaker an early edge over rival Eli Lilly.

Today’s stories:

• ByteDance Is Making A $23 Billion Bid, Eager To Take A Chunk Out Of Big Tech’s AI Lead
• US Regulators Approved Novo Nordisk’s Weight-Loss Pill

Try Finimize Pro